Plain-English translation of NCT06149689 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether mFOLFIRINOX — a combination of four chemotherapy drugs — works better when combined with radiation therapy for people with advanced pancreatic cancer. The study focuses on patients who have normal CA19-9 levels (a tumor marker), because early research suggests this group may respond especially well to this combination of the medication and radiation.
Pancreatic cancer is very difficult to treat, and most patients are diagnosed at an advanced stage when survival rates are low. Earlier research suggested that patients with normal tumor markers might benefit more from combining chemotherapy with radiation, so researchers want to formally test whether this combined approach improves outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive the chemotherapy medication as an infusion every two weeks, with each four-week period counting as one treatment cycle. After approximately four to six cycles of chemotherapy, you would receive radiation therapy targeted at your tumor. Throughout the study, you would have regular check-ups and blood tests every four weeks to monitor how well the treatment is working and to watch for side effects. After radiation therapy, your follow-up care would be guided by current cancer treatment guidelines.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fudan University
Enrollment target
~30 participants
Started
January 2024
Primary completion
October 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ying Yang, MD
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.